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Abstract 76 
 77 
Chromosomal translocations are now well understood to not only constitute signature 78 
molecular markers for certain human cancers but often also to be causative in the 79 
genesis of that tumor.  Despite the obvious importance of such events, the molecular 80 
mechanism of chromosomal translocations in human cells remains poorly understood.  81 
Part of the explanation for this dearth of knowledge is due to the complexity of the 82 
reaction and the need to archaeologically work backwards from the final product (a 83 
translocation) to the original unrearranged chromosomes to infer mechanism.  Although 84 
not definitive, these studies have indicated that the aberrant usage of endogenous DNA 85 
repair pathways likely lies at the heart of the problem.  An equally obfuscating aspect 86 
of this field, however, has also originated from the unfortunate species-specific differences 87 
that appear to exist in the relevant model systems that have been utilized to investigate 88 
this process.  Specifically, yeast and murine systems (which are often used by basic 89 
science investigators) rely on different DNA repair pathways to promote chromosomal 90 
translocations than human somatic cells.  In this chapter, we will review some of the 91 
basic concepts of chromosomal translocations and the DNA repair systems thought to 92 
be responsible for their genesis with an emphasis on underscoring the differences 93 
between other species and human cells.  In addition, we will focus on a specific subset 94 
of translocations that involve the very end of a chromosome (a telomere).  A better 95 
understanding of the relationship between DNA repair pathways and chromosomal 96 
translocations is guaranteed to lead to improved therapeutic treatments for cancer. 97 
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5.  Introduction 129 
 130 
The concept of chromosomal translocations — in which a portion of one chromosome 131 
breaks off and fuses inappropriately to another chromosome —  has been part of the 132 
scientific consciousness for the better part of eight decades.  Chromosomal translocations 133 
were first described by Karl Sax in 1938 (Sax 1938) and then elaborated by Barbara 134 
McClintock in the construction of ˗˔ˡ ˢ˔˜˘˝ː˛ ˶ˑˡ˔ː˚ː˖˔-fusion-ˑˡ˘˓˖˘˝˖˷ [BFB] model 135 
during the 1940s (McClintock 1941).  Chromosomal translocations gained significant 136 
clinical relevance a couple of decades later when it was demonstrated that a single 137 
recurring chromosomal translocation (the Philadelphia chromosome) was often found in 138 
patients suffering from leukemia (Nowell 1962; Rowley 1973).  Chromosomal 139 
translocations are now well understood to not only constitute signature molecular markers 140 
of human cancers (solid tumors in addition to blood cancers) but to be causative in their 141 
genesis as well (Lieber 2016; Grade et al. 2015).  As such, these translocations become 142 
extremely important for clinical diagnostics as well as treatment-related options, 143 
respectively.  Moreover, with the advent of comprehensive cancer genome sequencing, 144 
it is now appreciated that translocations, causative or not, are a common feature of 145 
human tumors (Stratton et al. 2009; Bunting and Nussenzweig 2013).  It is not 146 
surprisingly, therefore, that interest in identifying and quantitating chromosomal 147 
translocations has increased exponentially in the past decade.  As a consequence of 148 
this interest — and the experimentation associated with it — tens of thousands of 149 
translocations in a veritable bevy of different human cancers have been catalogued and 150 
characterized (Stratton et al. 2009; Lieber 2016).  While incredibly rich in molecular 151 
information, most of these studies suffer (biologically speaking) in being retrospective; 152 
that is, the mechanism for how the translocation occurred is often (correctly or incorrectly) 153 
simply inferred after the fact from the junctional sequences present at the site of a 154 
chromosomal translocation. 155 
To try and address this dearth of mechanistic knowledge, this chapter will focus on 156 
the relationship between DNA repair (specifically DNA double-strand break [DSB] repair) 157 
and chromosomal translocations.  An understanding of DNA DSB repair is paramount to 158 
our discussion because it seems obvious, if only intuitively, that a chromosomal 159 
translocation is the result of aberrant DNA DSB repair (Bohlander and Kakadia 2015; 160 
Iliakis et al. 2015; Roukos and Misteli 2014).  However, DNA DSB repair is infrequently 161 
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— and probably only rarely — aberrant because it is responsible for the stability of the 162 
genome.  Thus, it needs to be appreciated and emphasized that chromosomal 163 
translocations are by far the exception to the rule of the normally helpful processes 164 
(predominately DNA DSB repair) that keep the genome stable. 165 
It is a tautology and a fact appreciated by all cancer researchers that a stable 166 
genome is highly desirable and is inherently anti-oncogenic.  While this perspective is 167 
basically sensible, it is also important to remember that complete stability is antithetical 168 
with evolution/life.  That is, perfect immutability is contrary to the process of evolution 169 
and thus nature must maintain a balance between accurate DNA repair and the formation 170 
of mutations (i.e., the lack of — or mis-repair of — DNA) upon which selection can act.  171 
Thus, all DNA repair processes, DNA DSB ˡ˔˟ː˘ˡ ˘˝˒˛ˤ˓˔˓, ˗ː˥˔ ː ˑ˘ˣ ˞˕ ˶ˢ˛˞˟˟˘˝˔ˢˢ˷ 172 
inherent in their mechanism.  It is likely that chromosomal translocations are the result 173 
of one of these rare sloppy DNA DSB repair events.  Trying to identify how, why and 174 
when such events occur; and perhaps most importantly — whether they can be abrogated 175 
— is the clinically relevant goal for this field. 176 
  177 
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6.  DNA Damage 178 
 179 
As elaborated above, the human genome needs to be nearly (but not completely) 180 
immutable in order to ensure the survival of the species.  This turns out to be an 181 
extremely tall order as the human genome is constantly being chemically assaulted by 182 
both endogenous and exogenous factors.  The endogenous sources of damage likely 183 
vary from cell type to cell type, but can include: lesions associated with aberrant lymphoid 184 
gene recombination, DNA replication errors, transcriptional errors, the formation of reactive 185 
oxygen species during oxidative phosphorylation, as well as the spontaneous depurination 186 
or deamination of nucleotides [nts] due to the proximity of DNA to adjacent water 187 
molecules (Tubbs and Nussenzweig 2017) or the aberrant action of cellular deaminases 188 
(Swanton et al. 2015).  Exogenous sources of DNA damage include, but are certainly 189 
not limited to, exposure to ultraviolet light, chemotherapeutic drugs, or ionizing radiation.  190 
Indeed, in toto, it is estimated that each human cell sustains an astronomical ~70,000 191 
lesions per day (Tubbs and Nussenzweig 2017).  Importantly, however approximately 192 
69,975 of these lesions result in DNA damage on only one strand of the DNA duplex.  193 
Thus, although the type of damage can vary extensively and certain types of lesions 194 
require discrete DNA repair pathways (expanded upon in the next section) these 195 
processes are inherently high fidelity as a consequence of having an undamaged DNA 196 
strand upon which to template the repair events.  Thus, in human cells there is a 197 
surprisingly high level of DNA damage occurring on a daily basis that is nearly completely 198 
neutralized by conservative DNA repair pathways that utilize undamaged DNA to restore 199 
genome integrity. 200 
In contrast to all the other types of lesions combined, human cells suffer only about 201 
25 DSB lesions per cell per day (Tubbs and Nussenzweig 2017).  Again, the exact 202 
cause of the DSB can vary greatly depending upon the cell type.  Some likely occur 203 
due to aberrant lymphoid recombination processes (Lieber 2016), whereas others may 204 
be due to reactive metabolic oxygen production, DNA replication errors (Barnes and 205 
Eckert 2017) or the inappropriate action of cytidine deaminases (Knisbacher et al. 2016).  206 
Whatever their exact origin, DNA DSBs are uniquely toxic to cells because when both 207 
strands of the chromosome are damaged most of the time the only way to restore the 208 
chromosome to its original state is if an undamaged homologous chromosome (or sister 209 
chromatid if the DSB should occur during S phase of the cell cycle) is available to 210 
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template the repair event.  As a consequence, DSBs are inherently more mutagenic 211 
than most other types of lesions because of the difficultly in enacting their proper repair.  212 
A second parameter, which is relevant to this chapter, is that for all the other lesions, 213 
not only can the undamaged DNA strand help to enact error-free repair, but it also 214 
perforce holds the chromosome intact.  In contrast, the formation of a DSB generates a 215 
window of opportunity, however small, for the two chromosomal fragments to move away 216 
from one another.  If this happens, the chances of one of thoˢ˔ ˕ˡː˖˜˔˝ˣˢ ˶ˡ˔˟ː˘ˡ˘˝˖˷ 217 
itself onto another chromosome (i.e., causing a translocation) rises astronomically. 218 
In summary, the vast majority of the DNA lesions that a human cell experiences on 219 
a daily basis are generally rapidly and correctly repaired and are likely not relevant for 220 
the genesis of chromosomal translocations.  Importantly, this is not to say that these 221 
types of lesions cannot cause chromosomal translocations.  It is just likely that it is not 222 
a single single-stranded lesion per se that can trigger translocations, but the juxtaposition 223 
of two closely spaced single-strand lesions that give rise to a de facto DSB that are the 224 
culprit.  Thus, DSBs and DNA DSB repair (or the lack thereof) have been firmly 225 
established as being mechanistically responsible for chromosomal translocations. 226 
  227 
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7.  DNA Repair 228 
 229 
7.1  DNA Repair Involving only a Single Strand 230 
Due to the broad spectrum of lesions that can occur to DNA it is not surprising that 231 
discrete DNA repair pathways have evolved to correct these life-threatening alterations.  232 
Of all the lesions that damage only a single-strand of DNA most result in the formation 233 
of only a singly modified nt or an abasic site.  These lesions are readily repaired by 234 
the base excision repair pathway (Figure 1A).   This process involves the action of DNA 235 
gylcosylases, apurinic or apyrimidinic endonucleases and phosphodiesterases that 236 
ultimately convert the lesion into a single-stranded nick.  This nick is then filled in by a 237 
DNA polymerase and sealed by a DNA ligase (Wallace 2014). 238 
When the DNA lesion is bulkier than a single standard nt or when nts are fused 239 
together (e.g. via the formation of pyrimidine dimers) then a more complicated repair 240 
pathway, nucleotide excision repair (Figure 1B), is utilized that is capable of restoring 241 
stretches of nts (up to 24 nts in humans) in one event.  In nucleotide excision repair, 242 
the bulkier lesion is recognized by a multi-subunit protein complex that introduces nicks 243 
5' and 3' of the lesion.  The offending lesion is then removed as an oligonucleotide by 244 
the action of a helicase and the resulting ~20 nt gap is filled in by a polymerase and 245 
then sealed by a DNA ligase (Spivak 2015). 246 
A third common type of lesion is the mis-incorporation of nucleotides and/or 247 
generation of small insertions or deletions [indels] during DNA replication.  These types 248 
of lesions are repaired by mismatch repair (Figure 1C).  The mismatch repair machinery 249 
consists of large heterodimeric complexes that scan DNA and look for helical distortions 250 
due to the mispairing or indels.  These complexes recruit additional factors including 251 
endonucleases that nick and exonucleases that degrade one of the strands resulting in 252 
the removal of the offending mispaired nucleotide and some flanking nucleotides.  As 253 
before, the resulting gap is subsequently filled in by a DNA polymerase and sealed by 254 
a DNA ligase (Li et al. 2016). 255 
All three of the above processes (base excision repair, nucleotide excision repair 256 
and mismatch repair) are critical for cellular and organismal well-being.  Mutation of any 257 
of the factors associated with these pathways is generally either lethal or oncogenic, 258 
(although, pertinently, in the latter scenario not usually associated with chromosomal 259 
translocations).  The importance of single-stranded DNA repair for genome stability is 260 
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further evidenced by the awarding of the 2015 Nobel Prize in Physiology or Medicine to 261 
the investigators responsible for the discovery and/or initial characterization of these DNA 262 
repair pathways (Kunkel 2015). 263 
 264 
7.2  DNA Double-Strand Break Repair 265 
7.2.1  C-NHEJ 266 
Although DNA DSB lesions occur proportionately much less frequently than single-267 
stranded lesions, they are so toxic that cells have evolved multiple pathways that utilize 268 
hundreds of genes to make sure the DSBs are quickly and (semi)-accurately repaired.  269 
The two major pathways are nonhomologous end joining [NHEJ] (Woodbine et al. 2014; 270 
Lieber 2010) and homology-dependent repair [HDR] (Jasin and Rothstein 2013). 271 
In higher eukaryotes, DNA DSB repair proceeds most frequently by a process that 272 
does not require extended regions of homology.  Specifically, mammalian cells — and 273 
humans in particular — have evolved a highly efficient ability to join nonhomologous DNA 274 
molecules together (Roth and Wilson 1985).  This pathway is referred to as classic 275 
NHEJ [C-NHEJ] and it is generally error-prone.  The evolution of a repair pathway that 276 
is error-prone may seem paradoxical but is likely due to 1) the increased percentage of 277 
non-coding DNA in higher eukaryotes, a feature that more readily tolerates imprecise 278 
rejoining (a luxury that bacteria and lower eukaryotes do not have) and 2) the requirement 279 
for productive error-prone repair during lymphoid recombination processes to generate a 280 
large immune repertoire. 281 
Many of the details of C-NHEJ have been worked out, and the process is well 282 
(albeit certainly not completely) understood.  Following the introduction of a DSB into a 283 
chromosome, DNA Ligase IV [LIGIV] will often (if possible) attempt to immediately and 284 
precisely rejoin the broken ends to generate a perfect repair event.  Exactly how 285 
frequently such "error-free" C-NHEJ repair occurs is not known (Betermier et al. 2014), 286 
but it is now appreciated that it can occur much more frequently than had been believed 287 
(Oh et al. 2014; Waters et al. 2014).  At least some fraction of the time, however, the 288 
ends cannot be properly rejoined (due, for example, to the loss of nts and/or to aberrant 289 
adducts at the break site).  In these instances, the ends are bound by the Ku86:Ku70 290 
heterodimer [Ku; reviewed by (Hendrickson et al. 2006)], a highly abundant protein 291 
complex that binds to the broken DNA ends to prevent unnecessary DNA degradation 292 
(Figure 2).  The binding of Ku to the free DNA ends subsequently recruits and activates 293 
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the DNA-dependent protein kinase complex catalytic subunit [DNA-PKcs, (Jette and Lees-294 
Miller 2015; Blackford and Jackson 2017)].  DNA-PKcs:DNA-PKcs homotypic interactions 295 
(one molecule on each end of the DSB), in turn, are the critical feature required for 296 
synapsis, which retains the two broken ends near one another (Sibanda et al. 2017; 297 
Spagnolo et al. 2006).  Once a Ku:DNA-PKcs dimer [also referred to as the DNA 298 
dependent protein kinase complex; DNA-PK] is properly assembled at the broken ends 299 
it, in turn, activates a tightly-associated nuclease, Artemis (Moshous et al. 2003), to help 300 
trim any damaged DNA ends.  The extent of deletion is usually only a few nts and 301 
generally does not extend much beyond 25 nts with few exceptions (Hendrickson et al. 302 
1990; Gauss and Lieber 1996; Lieber 2010).  Subsequently, the X family polymerases 303 
mu and lambda fill in missing nucleotides (Lieber 2010).  The rejoining of the DNA DSB 304 
requires the recruitment (Critchlow et al. 1997b) of LIGIV and accessory factors: Paralog 305 
of XRCC4 and XLF [PAXX, (Ochi et al. 2015)], X-ray cross complementing group 4 306 
[XRCC4, (Critchlow et al. 1997a; Li et al. 1995)] and/or XRCC4-like factor/Cernunnos  307 
[XLF, (Ahnesorg et al. 2006; Buck et al. 2006)] (Figure 2).  Finally, it is relevant to note 308 
that most of the cells in a human being are either not cycling or in G1 phase of the 309 
cell cycle.  Because HDR (described below) is predominately restricted to cells in S 310 
phase (when a sister chromatid may be available for repair) C-NHEJ is perforce the 311 
preferred repair pathway in human cells and this accounts for its frequent usage.  In 312 
summary, in humans the predominant pathway of DSB repair is C-NHEJ and it first 313 
utilizes LIGIV to try and simply re-ligate the ends of a DSB back together.  Failing at 314 
that, C-NHEJ keeps the ends in proximity, polishes them up by limited resection and 315 
polymerization as needed and then uses LIGIV to religate the ends.  Due to the nuclease 316 
and polymerase action on one or both of the ends, small indels are a classic and 317 
frequent hallmark of chromosomal junctions repaired by C-NHEJ. 318 
 319 
7.2.2  A-NHEJ 320 
It had long been appreciated that the kinetics of C-NHEJ were biphasic — most (~80%) 321 
of the ends were rejoined quickly (within 15' to 30' of the chromosome breaking), but 322 
some ends could take hours to finally be rejoined.  For many years this was interpreted 323 
simply as some DSBs being "easier" to repair than others.  It was the laboratory of 324 
George Iliakis that first suggested that the slow phase of DSB repair may in fact 325 
represent a completely separate repair pathway (Wang et al. 2003).  This hypothesis 326 
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dovetailed nicely with earlier work done in yeast, which had genetically documented that 327 
in the absence of Ku, DSBs could be repaired by an alternative error-prone end-joining 328 
process that utilized microhomology (Boulton and Jackson 1996).  Although still somewhat 329 
controversial (Pannunzio et al. 2014) significant evidence has accumulated over the past 330 
15 years to substantiate the Iliakis hypothesis.  The hallmarks of this pathway (generally 331 
referred to as alternative nonhomologous end joining [A-NHEJ] to distinguish it from C-332 
NHEJ) are that it is Ku-independent and utilizes small (3 nt+) regions of (Frit et al. 2014; 333 
Iliakis et al. 2015; Boulton and Jackson 1996) to facilitate end joining.  The process of 334 
A-NHEJ is mechanistically simple and straightforward: both ends of the DSB are resected 335 
to generate 3' overhangs that are intermediate in length from those generated during C-336 
NHEJ (which are a few nucleotides at most) and HDR (which are often hundreds or 337 
thousands of nt long).  These resected ends can then base pair using now exposed 338 
stretches of "microhomology" (probably 3+ nt).  Nucleases are recruited to trim the flaps 339 
that are often generated and the nicks/ends are then sealed by a ligase (Frit et al. 340 
2014; Iliakis et al. 2015).  Thus, A-NHEJ is inherently an error-prone repair process as 341 
it always generates deletions including one of the two regions of microhomology and all 342 
the DNA in between the two patches of microhomology. 343 
Although the intellectual concept of how A-NHEJ occurs is clear, the genetics and 344 
biochemistry of the synapsis, processing and ligation of an A-NHEJ DSB repair event 345 
are still quite obscure leading to heavy debate by investigators in the field as to the 346 
precise mechanism.  Several studies have suggested that, like Ku for C-NHEJ, the 347 
protein poly(ADP-ribose) polymerase 1 [PARP1] may bind to the DNA ends (Figure 3).  348 
Indeed, there is evidence that PARP1 may even compete with Ku for access to the 349 
ends thereby determining the choice of the NHEJ pathways used for the repair of specific 350 
DSBs (Cheng et al. 2011). Alternatively, the repair complex meiotic recombination 351 
11/radiation sensitive 50/Nijmegen breakage syndrome 1 [MRE11/RAD50/NBS1; MRN] 352 
has also been implicated as the A-NHEJ end tethering activity (Dinkelmann et al. 2009; 353 
Xie et al. 2009).  Regardless of whether recognition or tethering of the ends is carried 354 
out by either PARP1 or MRN, resection is required to reveal the microhomology that will 355 
subsequently be used to mediate the repair event.  The initial resection is thought to be 356 
carried out by MRN and an associated nuclease, C-terminal interacting protein [CtIP].  357 
The short resection mediated by MRN/CtIP is then elongated by DNA exonuclease 2 358 
[DNA2] and/or exonuclease 1 [EXO1] (Mimitou and Symington 2008; Bernstein and 359 
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Rothstein 2009).  Once sufficient 3'-single-stranded DNA [ssDNA] overhangs have been 360 
generated the strands can anneal through the exposed microhomology (Figure 3).  361 
Moreover, the presence of microhomology modulates further resection activity and 362 
stabilizes the junction to facilitate ligation (Paull and Gellert 2000).  Finally, there are 363 
likely an additional number of enzymatic activities required for A-NHEJ including DNA 364 
polymerases and helicases, but most of these have only been inferred and not rigorously 365 
identified.  Perhaps the only two enzymatic activities which seem clearly required are 366 
DNA polymerase theta [POLQ] and a flap endonuclease activity needed to clip off 367 
mispaired strands.  In the case of POLQ, the evidence is strong that much of the 368 
microhomology introduced at DSB repair junctions is dependent upon this inherently 369 
error-prone enzyme (Ceccaldi et al. 2015; Mateos-Gomez et al. 2015).  The flap 370 
endonuclease activity is very likely supplied by the structure-specific nuclease complex 371 
excision repair cross-complementing 1/xeroderma pigmentosum gene F [ERCC1/XPF] 372 
(Ahmad et al. 2008).  Ultimately, the repaired DSB junction needs to be religated and 373 
DNA ligase III [LIGIII] appears to be the principal ligase used (Audebert et al. 2004; 374 
Della-Maria et al. 2011; Wang et al. 2005) although it is now clear that DNA ligase I 375 
[LIGI] can functionally substitute for LIGIII as well (Arakawa et al. 2012; Oh et al. 2014; 376 
Lu et al. 2016) (Figure 3). 377 
In summary, in order for A-NHEJ to occur, the broken DNA ends must somehow 378 
bypass being repaired by C-NHEJ (how this occurs is poorly understood).  If the ends 379 
are then subjected to significant, but nonetheless limited resection, they can utilize 380 
exposed microhomology to facilitate the repair event in a fashion that always generates 381 
deletions.  Although most [albeit certainly not all, (Pannunzio et al. 2014)] investigators 382 
now accept that A-NHEJ is a discrete DNA repair pathway, it is confounded by two 383 
serious shortcomings.  First, the most prominent feature of this pathway is the residual 384 
microhomology left at a repaired DNA DSB junction.  However, the definition of 385 
microhomology is often investigator-arbitrary and may include microhomologies as short 386 
as 1 or 2 nts.  Thus, there are a myriad of published studies where A-NHEJ is the 387 
inferred DNA repair mechanism because short microhomologies were observed at the 388 
repair junctions.  This is unfortunate because C-NHEJ can also use and generate 389 
microhomologies of 1 or 2 nts during repair (Pannunzio et al. 2014).  Thus, to be 390 
rigorous, at least 3 nt of homology is probably required before an assignment of A-NHEJ 391 
can confidently be given.  When this criterion is utilized, the vast majority of DNA repair 392 
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events suggested to be caused by A-NHEJ is dramatically reduced [see, for example 393 
(Chiarle et al. 2011)].  The second failing of A-NHEJ is that there is no specific factor 394 
required for the repair event.  LIGIII was one of the best candidates for such a factor, 395 
but recent work has shown that even this enzyme is dispensable for A-NHEJ (Arakawa 396 
et al. 2012; Oh et al. 2014).  Thus, until this situation is clarified it seems as if the best 397 
operational definition of A-NHEJ is: 1) a DNA DSB process that is Ku- and LIGIV-398 
independent but POLQ-dependent, 2) relies upon LIGIII or LIGI and 3) generates repair 399 
junctions with 3+ nts of microhomology. 400 
 401 
7.2.3  HDR 402 
Whereas C-NHEJ is the major DNA DSB repair pathway in human cells, DNA DSBs 403 
that occur in S phase of the cell cycle can instead be, and often are, repaired by HDR 404 
(Figure 4).  In HDR [reviewed by (Jasin and Rothstein 2013)], the DNA ends of the 405 
incoming DNA are likely extensively ˡ˔ˢ˔˒ˣ˔˓ ˣ˞ y˘˔˛˓ 3’-single-stranded DNA overhangs.  406 
As described above for A-NHEJ, the nuclease(s) responsible for this resection are the 407 
MRN:CtIP complex (which generates the initial resection) followed by the action of DNA2 408 
and EXOI (Mimitou and Symington 2008; Bernstein and Rothstein 2009).  The resulting 409 
overhangs are then coated by replication protein A [RPA], a heterotrimeric single-stranded 410 
DNA binding protein, which removes the secondary structures from the overhangs 411 
[reviewed by (Iftode et al. 1999)].  The breast cancer allele 1 and 2 [BRCA1 and BRCA2, 412 
respectively] proteins and the Fanconi anemia protein N [FANCN] then help to recruit 413 
radiation sensitive 51 [RAD51] to the overhangs (Venkitaraman 2014).  RAD51 is the 414 
key strand exchange protein in HDR [reviewed by (Thacker 2005)].  In humans, there 415 
are at least seven Rad51 family members and almost all of them have been implicated 416 
in some aspect of HDR and also in human disease.  Strand invasion into the homologous 417 
chromosomal sequence requires RAD54 [radiation sensitive 54] and DNA replication.  418 
Rad54 is a double-stranded DNA-dependent ATPase that can remodel chromatin and it 419 
probably plays critical roles at several steps in the recombination process [reviewed by 420 
(Heyer et al. 2006)].  In particular, Rad54 is critical for stabilizing the Rad51-dependent 421 
joint molecule formation as well as for promoting the disassembly of Rad51 following 422 
exchange (Solinger et al. 2002).  Strand exchange generates an interdigitated set of 423 
strands that can be resolved into a complicated set of products.  In mitotic cells most 424 
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of the intermediates are resolved as non-crossover products by dissolving the 425 
interdigitated strands back into their original duplexes after sufficient DNA replication has 426 
occurred to restore the genetic information lost at the site of the DSB (Figure 4A).  The 427 
dissolution process requires the action of the Bloom syndrome gene, topoisomerase 3 428 
and RecQ-mediated genome instability homolog 1 [BLM, TOPO 3, RMI1, respectively] 429 
complex (Wu and Hickson 2003).  Less frequently the second end of DNA is captured 430 
and a covalently closed "Holliday junction" (Holliday 1964) is formed that can be resolved 431 
as either non-crossover products (which are functionally identical to dissolution) or 432 
crossover products (Figure 4B).  The resolution of Holliday junctions is complicated and 433 
in human cells appears to be carried out by at least three partially, redundant resolvases 434 
consisting of mutagen sensitive 81/essential meiotic endonuclease 1 [MUS81/EME1, 435 
respectively], synthetically lethal with genes of unknown function (X) 1 and 4 [SLX1 and 436 
SLX4, respectively], and general homolog of endonuclease 1 GEN1] (Matos and West 437 
2014).  Finally, LIGI is utilized to covalently seal any nicks left in the DNA. 438 
Although HDR is often referred to as error-free repair, that characterization is only 439 
partially true.  Thus, in the case of non-crossover events in which the repair is templated 440 
from a sister chromatid the DSB is in fact repaired in an error-free fashion.  However, 441 
when a homolog, rather than a sister chromatid, is utilized there is a risk of the loss of 442 
heterozygosity and uniparental disomy as observed in several developmental disorders 443 
and numerous tumor types (Tuna et al. 2009).  In summary, human somatic cells express 444 
all of the gene products needed to carry out HDR.  These events occur, however, only 445 
at very low frequency and usually only in S phase due to the preferred usage of NHEJ. 446 
In summary, human cells can repair DNA DSBs by at least three discrete pathways: 447 
C-NHEJ, A-NHEJ and HDR.  How pathway choice (which pathway is utilized in which 448 
cells during which phases in the cell cycle, etc.) is biochemically determined is the focus 449 
of much research.  Regardless, from a logistical perspective, one thing that clearly 450 
differentiates these repair pathways is their reliance on different DNA ligases to complete 451 
the reaction.  Thus, C-NHEJ utilizes exclusively LIGIV, whereas A-NHEJ prefers to use 452 
LIGIII (although it can utilize LIGI) and HDR uses exclusively LIGI.  In conclusion, until 453 
better biochemical or genetic markers become available, ligation is one the most 454 
distinguishing features of these repair pathways. 455 
 456 
8.  Translocations 457 
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8.1.  DSBs and Translocations 458 
As enumerated above, DNA DSBs in human cells can occur either spontaneously or 459 
through exposure of the cells to environmental toxins.  The vast majority of the time, 460 
the two ends of a DSB are rejoined back to one another either by C-NHEJ, A-NHEJ or 461 
HDR with a varying loss of genetic information, but in a fashion that almost always 462 
restores genome stability.  Rarely, one or both ends of a DSB will be incorrectly rejoined 463 
to another DSB end resulting in a translocation.  The biological consequences of this 464 
can be enormous as translocations can inactivate tumor suppressor genes, activate 465 
oncogenes or make new chimeric oncogenes (Bunting and Nussenzweig 2013; Bohlander 466 
and Kakadia 2015; Lieber 2016).  All of these scenarios promote the formation of tumors. 467 
Translocations can occur within a chromosome (an intrachromosomal translocation) 468 
which can result in inversions or to another chromosome (interchromosomal translocation).  469 
In the latter case, the simplest outcome is a reciprocal translocation where the proximal 470 
portion of one chromosome is joined to the distal portion of another chromosome and 471 
vice versa.  Needless to say, since the occurrence of any one DSB is a relatively rare 472 
event (only 25 DSBs, per cell, per day) the likelihood of concomitant DSBs existing in 473 
the same cell at the same time is quite small and likely explains why translocations 474 
occur so much less frequently than other types of mutations.  The only situation where 475 
two DSBs are not required is when one of the DSBs is the natural end of a chromosome; 476 
i.e., a telomere.  As we will discuss below, this is a specialized case of translocation.  477 
In all other cases, there is a requirement for 2 DSBs to exist simultaneously in order 478 
for a translocation to occur.  The basic, but as yet still unanswered, question that drives 479 
virtually all research in this field is why are these DSBs simply not repaired normally?  480 
That is, two DSBs yield four DNA ends: 1 and 2 as well as 3 and 4.  In normal repair 481 
reactions end 1 would get re-joined to 2 and end 3 would become re-joined to 4.  In a 482 
translocation, however, 1 joins to 3 (or 4) and 2 joins to 4 (or 3).  Why and how the 483 
ends of a DSB become available to join with an end other than the one they were 484 
normally connected with is key to understanding the genesis of translocations. 485 
 486 
8.1.1.  Of Men, Mice and Translocations 487 
Before a discussion of the mechanistic aspects of this process can begin however, it is 488 
important to understand that the translocations that occur in human cells appear to arise 489 
by a different process than translocations that occur in the laboratory workhorse model 490 
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organism, the mouse.  This appears to be an exceptionally unfortunate biological 491 
difference as the mouse is used for a veritable plethora of cancer modeling studies and 492 
an enormous amount of pre-clinical cancer research is carried out with the mouse. 493 
In the mouse, it is manifestly compelling that translocations are mechanistically 494 
dependent upon A-NHEJ.  This conclusion rests upon at least three pieces of evidence.  495 
First, in the mouse, when genes involved in C-NHEJ are mutated the translocation 496 
frequency actually increases (Zhang et al. 2010; Boboila et al. 2010).  This observation 497 
is consistent with the interpretation that in the absence of C-NHEJ that there is likely a 498 
greater cellular reliance on A-NHEJ.  Second, when DNA sequence analyses are utilized 499 
to investigate the junctional diversity of translocations in the mouse, the frequency of 500 
microhomology — a quasi-hallmark of A-NHEJ — found at the repair site is quite high 501 
(Chiarle et al. 2011; Frock et al. 2015).  As noted above, however, the appearance of 502 
microhomology in and of itself is not unequivocally proof of the use of A-NHEJ.  Thus, 503 
in one very large study of translocations carried out by the Alt laboratory 75 to 90% of 504 
all translocations had microhomologies of 1 to 5 nts at the breakpoint junction.  However, 505 
only 10% of those same junctions were 5 nts or longer (Chiarle et al. 2011).  In 506 
conclusion, while clearly not unequivocal, these data are consistent with the use of A-507 
NHEJ.  Third, and perhaps the strongest piece of data, comes from a demonstration 508 
that genetic ablation of nuclear LIGIII, reduced the occurrence of translocations in the 509 
mouse (Simsek et al. 2011).  In summary, the increase in translocations when C-NHEJ 510 
is absent, the frequent use of microhomology at translocation breakpoints and the 511 
reduction of translocations when LIGIII is absent, compellingly indicate that translocations 512 
in the mouse are LIGIII-dependent and likely mediated by A-NHEJ. 513 
In contrast (and certainly confusingly), by the same set of criteria it appears as if 514 
translocations in human cells are mediated by C-NHEJ.  Thus, in contrast to the mouse, 515 
mutations in C-NHEJ genes LIGIV and XRCC4 greatly reduce the frequency of 516 
translocations in human somatic cells (Ghezraoui et al. 2014; Jones et al. 2014; Liddiard 517 
et al. 2016).  In addition, although microhomology can be found at translocations 518 
breakpoint junctions in human tumors (Tsai et al. 2008), the frequency and amount of it 519 
is generally small (Stephens et al. 2009; Berger et al. 2012).  Finally, the functional 520 
inactivation of LIGIII has little to no impact on translocations in human somatic cells 521 
(Ghezraoui et al. 2014).  It should be noted, however, that inhibition of PARP1, an A-522 
NHEJ gene, reduced translocations in some human cells (Wray et al. 2013; Byrne et al. 523 
  
 
 
19 
2014), but not in others (Liddiard et al. 2016).  This latter observation notwithstanding, 524 
the reduction in translocations when C-NHEJ is absent, the infrequent use of 525 
microhomology at translocation breakpoints and the lack of an impact on the frequency 526 
of translocations when LIGIII is absent, compellingly indicate that most translocations in 527 
human cells are LIGIV-dependent and likely mediated by C-NHEJ. 528 
Needless to say, these observations raise the question of why a seemingly similar 529 
process should be mechanistically so different in these two organisms.  To date, there 530 
is no clear answer.  The most likely explanation has to do with species-specific 531 
differences in the factors that make up the DSB repair pathways.  For example, DNA-532 
PKcs is the key C-NHEJ factor that tethers the two ends of a DSB together through 533 
homodimerization (Sibanda et al. 2017; Spagnolo et al. 2006).  Relevantly, DNA-PKcs is 534 
more abundant (by ~ an order of magnitude) in human cells than it is in rodent cells 535 
(Finnie et al. 1995).  Thus, the reduced quantities of DNA-PKcs (and presumably therefore 536 
reduced numbers of tethered ends) may provide A-NHEJ in the mouse with additional 537 
windows of opportunity for the ends to dissociate and be conscripted by A-NHEJ factors, 538 
whereas in human cells, with a superabundance of DNA-PKcs [there are estimated to be 539 
between one-half to one million molecules of DNA-PKcs in every human cell; (Meek et 540 
al. 2008)] C-NHEJ is the dominant repair pathway.  The obvious follow-up question of 541 
why human cells should contain so much more DNA-PKcs than rodents is unfortunately 542 
not biochemically obvious, but the empirical fact that they do likely provides at least a 543 
partial answer for why the two organisms utilize the C-NHEJ and A-NHEJ pathways 544 
differentially.  In addition, it is well known that chromatin organization and epigenetic 545 
modifications can affect the mutation rate across genomes (Schuster-Bockler and Lehner 546 
2012; Tubbs and Nussenzweig 2017).  Specific chromatin features and epigenetic marks 547 
are unlikely to be highly conserved across species and these differences may also 548 
impact upon the process of translocations.  Finally, it is now appreciated that at least 549 
some of the endogenous DSBs generated in vertebrate cells may be due to the aberrant 550 
action of apolipoprotein B editing complex 3 [APOBEC3], a cytidine deaminase capable 551 
of introducing closely spaced nicks into the DNA (Swanton et al. 2015; Tubbs and 552 
Nussenzweig 2017).  Importantly, there is a single APOBEC3 gene in the mouse, 553 
whereas in humans that locus has been significantly expanded to eight functional 554 
isoforms.  Thus, differences in APOBEC3 expression could certainly causes significant 555 
differences in either the frequency and/or location of DSBs in the genome.  Whatever 556 
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the correct answer(s) may be, it is important to appreciate that particular care must be 557 
taken in interpreting or extrapolating experimental results obtained in rodent model 558 
systems to humans since some of the basic biology appears to be different [discussed 559 
at length as well by (Lieber 2016)]. 560 
 561 
8.1.2.  Spatial Karma and Translocations 562 
Regardless of which pathway of end joining (C-NHEJ or A-NHEJ) is used for repair, 563 
why are these processes not always faithful?  The correlation of translocations with 564 
aberrant A-NHEJ is easiest to reconcile.  Thus, while PARP1 can bind tightly to DNA 565 
ends, it is not known to homodimerize.  Moreover, while some studies have suggested 566 
that MRN, or subunits thereof, are capable of homodimerization (Williams et al. 2008) 567 
there is frankly no A-NHEJ factor comparable to DNA-PKcs.  As a consequence of this, 568 
it seems likely that the ends of a DSB that are being repaired by A-NHEJ may not be 569 
as synaptically as stable as ends being repaired by C-NHEJ and therefore simply stand 570 
a statistically higher chance of separating from one another before the repair event is 571 
completed.  This model dovetails nicely with the reduced amounts of DNA-PKcs observed 572 
in rodents and their correspondingly greater propensity to utilize A-NHEJ in the formation 573 
of translocations.  The flip side of this rationalization is more complex.  Thus, in humans, 574 
where C-NHEJ apparently predominates, why does the end of DSB ever become capable 575 
of joining to an end other than its cognate end?  Indeed, it is well known (albeit mostly 576 
from mouse studies) that C-NHEJ is more likely to join DSBs intrachromosomally rather 577 
than interchromosomally (Mahowald et al. 2009; Chiarle et al. 2011).  In essence then, 578 
when C-NHEJ is utilized it is simply less likely that a translocation will result.  The most 579 
compelling explanation for the translocations that do result is that the DSBs may be 580 
spatially adjacent to one another.  For example, even early experiments on the spatial 581 
organization of the human genome noted that translocations often involved regions that 582 
were physically closer to one another than to other regions of the genome (Meaburn et 583 
al. 2007).  These observations have been confirmed and extended over the past decade 584 
as technology has improved the characterization of the large-scale organization of 585 
chromosomes (Roukos and Misteli 2014; Roukos et al. 2013; Bohlander and Kakadia 586 
2015).  Thus, nuclear DSBs have a tendency not to move very much (Kruhlak et al. 587 
2006; Jakob et al. 2009) and this correlates well with the observation that more than 588 
80% of DSBs translocate to regions that are physically located to within 2.5 m of each 589 
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other (Roukos and Misteli 2014; Roukos et al. 2013).  In conclusion, the current best 590 
explanation for why translocations occur in human cells is "bad karma".  That is, a 591 
translocation likely only occurs when two concomitant DSBs are also spatially close to 592 
one another in the nucleus such that a synaptic complex (likely a requirement for repair) 593 
can form — albeit in these rare instances between non-cognate ends. 594 
 595 
8.1.3.  Selection, not the Translocation, Drives Cancer 596 
It is well known that particular translocations are the hallmark of certain cancers (Lieber 597 
2016; Bunting and Nussenzweig 2013).  However, it is important to appreciate that the 598 
predominance of a translocation in a tumor is due solely to the subsequent selection 599 
that is imposed upon all the translocations that may have occurred during the genesis 600 
of that tumor.  That is, if, and only if — and this is a stochastic probability — the 601 
translocation generates a novel chromosome that gives the cell a selective growth 602 
advantage, will these cells be subsequently amplified to generate the tumor.  Indeed, 603 
translocations that are oncogenic have invariably inactivated a tumor suppressor gene, 604 
activated an oncogene and/or created a chimeric gene that is acting as an oncogene.  605 
This event, however, is independent from the mechanism of the translocation; that is, 606 
there is nothing inherently oncogenic about translocations.  Both ends of a DSB have a 607 
similar propensity to translocate (Chiarle et al. 2011) and although there is a bias towards 608 
translocations happening near transcriptional start sites in the mouse (Chiarle et al. 609 
2011), this bias is not observed in human cells (Lieber 2016) (yet another difference 610 
between mice and humans).  Consequently, it is important to appreciate is that there is 611 
no evidence of directionality or specificity intrinsic to translocations themselves.  Thus, 612 
both ends of a broken chromosome likely have the potential to translocate to an infinite 613 
number of chromosomal locations and this is likely limited only by the spatial parameters 614 
discussed above. 615 
 616 
8.2  Considerations for when one DSB is a Telomeric End 617 
Up until now, all of the translocations that have been discussed were canonical ones 618 
requiring the formation of two DSBs and the generation of four DNA ends.  There is 619 
one biologically important scenario, however, where translocations can occur between a 620 
DSB and a "single-ended DSB" and hence only involve three DNA ends.  This scenario 621 
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occurs when the end of a chromosome, i.e., a telomere, participates in the translocation 622 
reaction. 623 
 624 
8.2.1 Telomeres Stabilize the Genome 625 
There are 46 chromosomes in a normal diploid human cell and because each 626 
chromosome has 2 ends, there are in principle 92 natural DSBs constitutively present in 627 
a cell.  Such a scenario, if it truly existed, would be lethal, so evolution has devised an 628 
answer in the form of telomeres.  Telomeres are specialized nucleoprotein structures 629 
that are found at the extreme termini of linear eukaryotic chromosomes.  Telomeres 630 
"cap" those ends and prevent the recognition of the chromosomal termini as DSBs by 631 
the cellular DNA damage response apparatus.  Telomeres consist of a repetitive 632 
hexameric tract of DNA (TTAGGG) bound by an evolutionarily-conserved complex of 633 
proteins collectively called Shelterin (de Lange 2005).  Importantly, ongoing cell division 634 
(i.e., aging) results in gradual telomere erosion (Harley et al. 1990), and ultimately, the 635 
loss of the end-capping function which, in the context of a functional DNA damage 636 
response, leads to the induction of a p53-dependent G1/S cell cycle arrest, known as 637 
replicative senescence (d'Adda di Fagagna et al. 2003).  This cell-intrinsic limit on 638 
replicative lifespan provides a stringent tumor suppressive mechanism.  However, in the 639 
absence of a fully functional DNA damage checkpoint response, older cells containing 640 
short dysfunctional telomeres (which are essentially one-ended DSBs) enter a state of 641 
crisis during which telomeres undergo fusion, either between sister chromatids (Figure 642 
5A), with interchromosomal telomeres (Figure 5B) or with non-telomeric DSBs, creating 643 
dicentric chromosomes and initiating BFB cycles (Counter et al. 1992; Murnane 2012).  644 
This, in turn, leads to the creation of genomic rearrangements, including the translocations 645 
that are common in cells from many different tumor types (Artandi et al. 2000; Shih et 646 
al. 2001).  The development of single-molecule approaches to characterize the sequence 647 
of telomere fusion events, has revealed that short dysfunctional telomeres are capable 648 
of recombining with both telomeric and non-telomeric loci across the genome (Liddiard 649 
et al. 2016; Letsolo et al. 2010).  Thus, whilst BFB cycles initiated because of telomere 650 
dysfunction can lead to chromosomal translocations (Murnane 2012), telomere fusions 651 
themselves can also lead directly to translocation events.  Intra-chromosomal telomere 652 
fusion involving sister-chromatids predominates over inter-chromosomal telomere fusion, 653 
which in turn is more frequent than inter-chromosomal fusion between telomeres and 654 
  
 
 
23 
non-telomeric loci (Liddiard et al. 2016).  The characteristics of the non-telomeric loci 655 
involved in telomere fusion have yet to be fully characterized, but thus far it is apparent 656 
that they occur predominantly within coding regions of the genome; indicating a potential 657 
role for chromatin structure and replication timing in conferring sensitivity to fusion 658 
(Liddiard et al. 2016).  Larger datasets documenting the specific loci involved in telomere 659 
fusion are required before a definition of these fusagenic loci can be provided and 660 
potential hot spots identified. 661 
Thus, telomere-dependent crisis is a key event in driving genomic instability and 662 
clonal evolution during the progression to malignancy; this is consistent with data and 663 
observations of telomere dynamics and fusion in a broad range of human tumor types 664 
in which extreme telomere erosion and fusion is observed that correlates with the 665 
presence of large-scale genomic rearrangements (Lin et al. 2010; Roger et al. 2013; 666 
Meeker et al. 2004).  Moreover, patients with tumors that display short dysfunctional 667 
telomeres, within the length ranges at which fusion can occur, exhibit a poorer prognosis 668 
and response to treatments (Lin et al. 2014; Strefford et al. 2015; Williams et al. 2017).  669 
Short dysfunctional telomeres have been identified in the very earliest lesions, including 670 
very small adenomatous colorectal polyps (Roger et al. 2013) and in leukemias prior to 671 
clinical progression (Lin et al. 2010).  Importantly, the short telomeres observed in early 672 
stage lesions are identical in length to those observed in more advanced disease clones, 673 
indicating that telomere length does not vary considerably during progression.  Together 674 
these data are consistent with the presence of short telomeres in the cell in which the 675 
initiating mutation occurred and that this dictates the telomere length distribution of the 676 
developing clone.  In this model, if the initiating cell contains short telomeres then the 677 
subsequent clone may have a "telomere-mutator" phenotype that drives genomic 678 
instability, translocations and clonal progression, whereas a cell with long telomeres gives 679 
rise to a clone with a more stable genome, which exhibits slower rates of clonal 680 
progression (92).  Finally, it is important to note that short dysfunctional telomeres have 681 
been observed in the majority of tumor types analyzed (Jones et al. 2012) and thus it 682 
appears that a period of telomere-driven genome instability may be a common mechanism 683 
underlying the progression to malignancy.  Therefore, there is a requirement to 684 
understand the mechanisms by which telomere dysfunction can facilitate genome 685 
instability. 686 
 687 
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8.2.2  Translocations Involving Telomeres Are Mechanistically Distinct 688 
Telomere fusion is clearly an important and physiologically relevant, mutational event.  689 
Key to the function of mammalian telomeres is the Shelterin complex that plays a 690 
fundamental role in protecting the natural chromosomal termini from aberrant NHEJ-691 
mediated joining events (de Lange 2005). For example, in the mouse, the abrogation of 692 
telomere recognition factor 2 [TRF2], a core component of Shelterin, confers a widespread 693 
telomere fusion phenotype (van Steensel et al. 1998) that is dependent upon the activity 694 
of LIGIV.  In contrast, fusions were readily detected in telomerase-deficient mice, with 695 
short dysfunctional telomeres, despite the absence of core components of C-NHEJ 696 
pathway, including DNA-PKcs or LIGIV (Maser et al. 2007; Rai et al. 2010).  Thus, in 697 
the mouse and in the context of short dysfunctional telomeres, which is likely the most 698 
biologically relevant form of telomere dysfunction, telomeres are no longer fully recognized 699 
by the Shelterin complex and the processing of telomere fusion appears to be mediated 700 
by either C-NHEJ or A-NHEJ. 701 
The view that telomere-mediated translocations may be mechanistically distinct from 702 
canonical two DSB-mediated translocations is consistent with the molecular analysis of 703 
telomere fusion events directly from human cells undergoing a telomere-driven crisis in 704 
culture.  These data show that fusion between short telomeres — ones that are almost 705 
completely denuded of telomere repeats — is accompanied by deletion and microhomology 706 
across the fusion points (Capper et al. 2007).  The deletion that accompanies telomere 707 
fusion, includes not just the telomere repeat array itself, but extends into the telomere-708 
adjacent DNA, up to the limit of the assays used (6.1 kb), the distribution of fusion 709 
points from the start of the telomere repeat arrays, indicates that deletion may be much 710 
more extensive.  This characteristic profile is also observed at telomere fusion junctions 711 
isolated from some human malignancies, including early-stage and pre-malignant lesions 712 
(Lin et al. 2010; Roger et al. 2013), as well normal human cells, in which rare stochastic 713 
telomeric deletion results in fusion (Capper et al. 2007; Lin et al. 2010; Roger et al. 714 
2013).  Finally, molecular analysis of fusion events following replicative telomere erosion 715 
in human cells carrying hypomorphic MRE11 alleles revealed a change in the mutational 716 
spectrum with an increase in insertions at the fusion point (Tankimanova et al. 2012).  717 
The reliance on MRE11, the extensive deletion and the high degree of microhomology 718 
that accompanied these human telomere fusions was indicative of error-prone processing 719 
of short dysfunctional telomeres via the A-NHEJ pathway and suggested that telomere-720 
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mediated fusions in human cells may be mechanistically fundamentally different than 721 
canonical two DSB-mediated translocations, which, as detailed above, appear to be 722 
predominately mediated by C-NHEJ. 723 
 724 
8.2.3  Translocations Involving Human Telomeres can be Mediated by LIGIII or 725 
LIGIV 726 
To experimentally test this idea, a study was undertaken utilizing human cell lines in 727 
which either nuclear LIGIII (Oh et al. 2014) or LIGIV (Oh et al. 2013) (and presumably 728 
A-NHEJ or C-NHEJ, respectively) had been inactivated by gene targeting.  A dominant-729 
negative version of human telomerase [DN-hTERT; (Hahn et al. 1999)] was then 730 
expressed in these cells to cause gradual telomere shortening and the status of the 731 
telomere stability was assessed by a single telomere length analysis [STELA; (Baird et 732 
al. 2003)] and single-molecule telomere fusion analyses.  These approaches allow one 733 
to either 1) quantitate the length of a single telomere, 2) detect and characterize the 734 
DNA sequence of translocations or 3) detect and quantitate sister chromatid:sister 735 
chromatid fusions/translocations.  These experiments demonstrated that translocations 736 
involving telomeres occurred in either LIGIII- or LIGIV-null cells (Jones et al. 2014).  737 
Thus, unlike canonical translocations, which are heavily dependent upon LIGIV, a high 738 
frequency of telomere-mediated translocations was still observed in LIGIV-null cells.  739 
There were, however, some parallels with canonical translocations.  Thus, the majority 740 
of the translocations that occurred in LIGIII-null cells (i.e., translocations perforce mediated 741 
by LIGIV) were biased 3:1 towards interchromosomal translocations, as is observed for 742 
canonical translocations.  Similarly, in LIGIV-null cells (i.e., translocations perforce 743 
mediated by LIGIII) while there were still interchromosomal translocations, telomere 744 
fusions were now biased 52:1 towards intrachromosomal sister chromatid fusion events 745 
(Jones et al. 2014).  These biases were so significant that they had a profound biological 746 
effect — cells that were LIGIII-null were not able to survive the DN-hTERT-induced crisis 747 
whereas those that were either wild type or LIGIV-null readily survived.  A parsimonious 748 
interpretation of this data is that the LIGIV-mediated interchromosomal translocations 749 
were predominately toxic und ultimately lethal for cells whereas the LIGIII-mediated 750 
intrachromosomal fusions provided a growth advantage that could be selected for during 751 
crisis.  This interpretation is consistent with the gene duplications and localized 752 
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amplifications that are associated with sister:sister fusion events that are not observed 753 
with interchromosomal translocations (Murnane 2012). 754 
These experiments beg the question as to why a telomere-mediated translocation 755 
(as compared to a interchromosomal DSB-mediated translocation) should be less reliant 756 
on C-NHEJ (and/or more reliant on A-NHEJ).  The most obvious difference is simply 757 
that while a shortened telomere can bind a single DNA-PK complex, there is no 758 
corresponding end to bind a second DNA-PK complex and hence there is a greatly 759 
reduced chance of forming a synaptic complex.  The lack of a synaptic complex 760 
presumably now permits the recruitment of A-NHEJ factors to the end and/or the 761 
displacement of the DNAPK complex from the end such that a higher frequency of A-762 
NHEJ-mediated fusions can occur.  Another factor that might influence the relative 763 
activities of A- and C-NHEJ at telomeres may be the nature of a short telomere, 764 
compared to a non-telomeric DSB.  The telomeres terminate not with a blunted-ended 765 
DSB, but instead have a large (200 to 300 nt) overhang composed of TTAGGG repeats 766 
(Wright et al. 1997).  This unique structure has the potential to fold into G-quadruplex 767 
structures (Xu et al. 2009) and may represent a non-canonical substrate for DNA repair 768 
activity that may favor the slower kinetics of the A-NHEJ pathway over that of C-NHEJ. 769 
 770 
8.2.4  Translocations Involving Human Telomeres can be Mediated by LIGI 771 
The above data strongly suggested that the geometry of the DNA ends and the availability 772 
of a requisite DNA ligase controls the type of translocations that can occur in human 773 
cells.  To extend these observations a follow-up study was carried out in which the 774 
frequency and kind of translocation was quantitated in cells that were genetically 775 
engineered to be deficient for both LIGIII and LIGIV, where, presumably, both C-NHEJ 776 
and A-NHEJ would be ablated.  In this experimental set-up the telomere was not 777 
gradually exposed by the expression of DN-hTERT as before, but was rapidly deleted 778 
by the use of a transcription activator-like effector nuclease [TALEN; (Ousterout and 779 
Gersbach 2016)].  A TALEN pair was designed to introduce a DSB 14 base pairs from 780 
the start of the telomeric TTAGGG repeat on the petite arm of chromosome 17.  Thus, 781 
this experimental system is somewhat of a hybrid between those measuring canonical 782 
fusions and the system to gradually uncover a telomere end by enforced DN-hTERT 783 
expression.  Specifically, the TALEN should generate a DSB with two ends, however, 784 
one of those ends is only a couple of kilobases long and consists solely of the telomeric 785 
  
 
 
27 
TTAGGG hexameric repeat.  It is unclear whether this end can function in a fashion 786 
similar to a canonical chromosomal end.  With this caveat in mind, it was reassuringly 787 
observed that in the absence of LIGIV a greatly decreased frequency of interchromosomal 788 
translocations was observed (Liddiard et al. 2016).  Very surprisingly, however, in the 789 
combined absence of LIGIII and LIGIV significant amounts of both inter-and 790 
intrachromosomal translocations were observed inter-chromosomal translocations were 791 
also detected albeit at a reduced frequency (Liddiard et al. 2016).  Interestingly, whilst 792 
the frequency of inter-chromosomal fusion events was decreased in the absence of 793 
LIGIV, intra-chromosomal sister chromatid fusion events appeared to be largely 794 
unchanged in the different genetic backgrounds tested.  Moreover, there were differences 795 
in the utilization of microhomology, with significantly greater microhomology observed at 796 
intra-chromosomal events compared to inter-chromosomal events.  Taken to together 797 
these data are consistent with a role for LIGIV-dependent C-NHEJ in driving 798 
interchromosomal telomere fusion and A-NHEJ being predominant for intrachromosomal 799 
sister chromatid telomere fusion.  These data were also important because they provided 800 
the first demonstration in human cells that LIGI can facilitate chromosomal translocations 801 
— both inter-chromosomal and intra-chromosomal sister chromatid translocations.  802 
Moreover, these data revealed considerable redundancy in the utilization of the specific 803 
ligases for end-joining, with LIGI being able to facilitate intra-chromosomal fusion as well 804 
as inter-chromosomal fusion, albeit less efficiently.  This may be discouraging from the 805 
clinical perspective, as these data indicate that attempts to inhibit human translocations 806 
using small molecule inhibitors to LIGIII and LIGIV (Singh et al. 2014) are destined to 807 
fail due to the robust ability of LIGI to compensate for their absence.  That said, any 808 
intervention that can skew the fusion spectrum towards inter-chromosomal events, 809 
creating a larger mutational burden on cells and influencing their ability to escape a 810 
telomere-driven crisis, may have clinical utility.  A deeper understanding of the key 811 
proteins involved in A-NHEJ and telomere fusion may identify additional therapeutic 812 
targets that could allow for more selective interventions into these pathways. 813 
 814 
9.  Summary and Future Considerations 815 
In summary, DSBs are normally repaired with high fidelity in the sense that the pieces 816 
of DNA that were contiguous before the DSB are contiguous after DNA repair, regardless 817 
of the "sloppiness" of the actual join.  In order for a canonical chromosomal translocation 818 
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to occur there needs to be two contemporaneous DSBs within a cell (which is a low 819 
frequency event) and the ends that were contiguous with one another before the DSBs, 820 
need to be rejoined aberrantly.  This (mis)rejoining of the ends is likely mediated, at 821 
least in part, by their spatial proximity within the nucleus with the closer that the DSB 822 
ends are to each other the greater the likelihood of a translocation occurring.  In the 823 
mouse, these events are predominately mediated by LIGIII/A-NHEJ whereas in human 824 
cells they are mediated by LIGIV/C-NHEJ.  When a telomere shortens or when it loses 825 
its protective proteinaceous cap, the Shelterin complex, it is treated by the cell as a 826 
one-ended DSB and can engage in the formation of translocations as well.  In this 827 
instance, however, both A-NHEJ and C-NHEJ seem to play an active role in mediating 828 
the resulting translocations.  Layered over all of this is an additional layer of complexity 829 
provided by the recent demonstration that LIGI can fully compensate for translocations 830 
that were previously exclusively or predominately ascribed to LIGIII/A-NHEJ or LIGIV/C-831 
NHEJ. 832 
As is often the case in biology, reality is often much more complex than first 833 
envisioned.  In the beginning, most models of chromosomal translocations invoked the 834 
aberrant use of either LIGIII or LIGIV.  It is now clear that the situation is significantly 835 
more complicated with all three DNA ligases capable of generating translocations in a 836 
fashion that likely depends upon the state of the cell cycle, the level of expression of 837 
the various ligases within a given cell type and whether one of the translocating ends 838 
is telomeric or not.  As a consequence, simplistic approaches of inhibiting a single ligase 839 
[and such specific inhibitors are not even currently available; (Singh et al. 2014)] are 840 
likely destined to fail.  Nonetheless, it is clear that in a human cell where all three 841 
ligases are expressed that inhibiting LIGIV will significantly decrease interchromosomal 842 
translocations, which could potentially be used to therapeutic benefit.  What is clinically 843 
perhaps more relevant however, is trying to inhibit the intrachromosomal sister 844 
chromatid:sister chromatid fusions as these appear to be critical for cells to escape crisis 845 
and thus become oncogenic (Jones et al. 2014).  In this scenario, inhibition of both LIGI 846 
and LIGIII will likely be necessary to achieve a therapeutic outcome.  Given that LIGI 847 
also has important functions in DNA replication (an essential cellular process) it is likely 848 
that such approaches will have significant toxic side effects.  Nonetheless, as more is 849 
learned about all three DNA ligases, and especially about how pathway choice for DSB 850 
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repair is regulated there is still significant cause for optimism that windows of opportunity 851 
for therapeutic intervention will be uncovered. 852 
  853 
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Figure Legends 1 
 2 
Figure 1.  Repair of lesions where one DNA strand is still intact.  (A) Base Excision 3 
Repair.  The schematic shows a small piece of double-stranded DNA (colored rectangles 4 
represent nucleotides) containing a singly modified nt (red diamond).  This lesion is 5 
repaired by the action of DNA gylcosylases, endonucleases and phosphodiesterases that 6 
ultimately convert the lesion into a single-stranded nick.  This nick is then filled in by a 7 
DNA polymerase and sealed by a DNA ligase.  (B)  Nucleotide Excision Repair.  The 8 
schematic shows two nts (colored lines) that are fused together (red diamond).  This 9 
lesion is recognized by a multi-subunit protein complex that introduces nicks 5' and 3' 10 
of the lesion.  The offending lesion is then removed as an oligonucleotide by the action 11 
of a helicase and the resulting ~20 nt gap is filled in by a polymerase and then sealed 12 
by a DNA ligase.  (C) Mismatch Repair.  The schematic shows two nucleotides (colored 13 
lines) where one base pair is mispaired (red diamonds).  The mispaired nts are 14 
recognized by mismatch heterodimeric complexes that recruit endonucleases that nick 15 
the DNA.  Exonucleases then degrade one of the strands resulting in the removal of 16 
the offending nt as well as some flanking nts.  As before, the resulting gap is 17 
subsequently filled in by a DNA polymerase and sealed by a DNA ligase. 18 
 19 
Figure 2.  A schematic depicting Classic Non-Homologous End Joining (C-NHEJ). The 20 
black lines represent strands of DNA.  First, the Ku heterodimer (orange ball) binds onto 21 
the ends of the DNA.  Ku then recruits DNA-PKcs (blue oval) and the homotypic 22 
interactions between two DNA-PKcs molecules tethers the ends together.  The nuclease 23 
Artemis (yellow PacManTM), which is physically associated with DNA-PKcs, can then 24 
remove any mispaired or damaged nucleotides from the ends.  Most missing nts are 25 
then replaced by the DNA polymerases  or  (green pentagon).  Finally, a ligase 26 
complex, consisting of DNA ligase IV (purple cylinder) and the accessory proteins PAXX 27 
(red half oval), XRCC4 (light green tear drop) and XLF (Carolina blue cropped pyramid) 28 
then religated the ends back together.  This process often results in indels (denoted by 29 
the red rectangle) at the site of repair. 30 
 31 
Figure 3.  A schematic depicting Alternative Non-Homologous End Joining (A-NHEJ).  32 
The black lines represent strands of DNA and the red rectangles blocks of 33 
  
 
 
2 
microhomology.  The broken ends may be held together either by PARP1 (Carolina blue 34 
hexagon) or by the MRN complex (orange oval).  The initial resection is carried out by 35 
MRN and CtIP (crimson PacManTM).  This short resection is then elongated by DNA2 36 
and/or EXO1 (light green PacManTM).  Once sufficient 3'-single-stranded DNA [ssDNA] 37 
overhangs have been generated the strands can anneal through the exposed 38 
microhomology.  The presence of microhomology stabilizes the junction.  The resulting 39 
flaps are likely cleaved off by the ERCC1/XPF heterodimer (yellow PacManTM).  Before 40 
ligation occurs it is also likely that POLQ (purple lightning bolt) may act on the DNA 41 
ends.  Ultimately, the repaired DSB junction is religated using either LIGIII (red cylinder) 42 
or LIGI (pink cylinder). 43 
 44 
Figure 4.  A schematic depicting Homology-Dependent Repair (HDR).  The black lines 45 
represent strands of DNA where a DSB has occurred and the blue lines represent an 46 
undamaged sister chromatid or a homologue.  In HDR, the DNA ends of the DSB are 47 
˔˧ˣ˔˝ˢiv˔l˨ ˡ˔ˢ˔˒ˣ˔˓ ˣ˞ ˨i˔l˓ 3’-single-stranded DNA overhangs.  As described for A-48 
NHEJ, the nuclease(s) responsible for this resection are the MRN:CtIP complex (which 49 
generates the initial resection; orange oval and crimson PacManTM, respectively) followed 50 
by the action of DNA2 and EXOI (light green PacManTM).  The resulting overhangs are 51 
then coated by RPA (red circles), which removes the secondary structures from the 52 
overhangs.  A complex of proteins including BRCA1, BRCA2, and FANCN (purple cloud) 53 
then help to recruit RAD51 (pink diamond) to the overhangs.  Strand invasion into the 54 
homologous chromosomal sequence requires RAD54 (yellow moon) and DNA replication 55 
(blue-green cloud).  Strand exchange generates an interdigitated set of strands that can 56 
be resolved into a complicated set of products.  (A) In mitotic cells most of the 57 
intermediates are resolved as non-crossover products by dissolving the interdigitated 58 
strands back into their original duplexes after sufficient DNA replication has occurred to 59 
restore the genetic information lost at the site of the DSB.  The dissolution process 60 
requires the action of the BLM/TOPO 3/RMI1 complex (green hexagon).  (B) Less 61 
frequently the second end of DNA is captured and a covalently closed "Holliday junction" 62 
is formed that can be resolved as either non-crossover products (which are functionally 63 
identical to dissolution) or crossover products.  The resolution of Holliday junctions is 64 
complicated and in human cells appears to be carried out by at least three partially, 65 
redundant resolvases consisting of mutagen sensitive 81/essential meiotic endonuclease 66 
  
 
 
3 
1 [MUS81/EME1, respectively], synthetically lethal with genes of unknown function (X) 1 67 
and 4 [SLX1 and SLX4, respectively], and general homolog of endonuclease 1 GEN1] 68 
(1) (light blue cloud).  Finally, LIGI (pink cylinder) is utilized to covalently seal any nicks 69 
left in the DNA.  Note that only the non-crossover product for Holliday Junction resolution 70 
is diagrammed. 71 
 72 
Figure 5. Short dysfunctional telomeres can be subjected to sister-chromatid fusion, or 73 
inter-chromosomal fusion events to create amplifications, deletion and non-reciprocal 74 
translocations.  (A) Gradual telomere erosion in the absence of functional DNA damage 75 
checkpoints, leads to short telomeres that are no longer protected by the Shelterin 76 
complex.  Fusion between sister-chromatids results in the formation of a dicentric 77 
chromosome, that can form a bridge between daughter cells at anaphase, that be 78 
subjected a breakage event.  Depending on the position of the break, this can lead to 79 
a daughter cell that has lost terminal sequences, or has an addition copy of a gene — 80 
in this example, gene B.  Further BFB cycles can lead to further amplification and 81 
deletion.  This process can be stopped by the healing of a DSB via the acquisition of 82 
a de novo telomere, either by telomerase-mediated extension or by recombination with 83 
a pre-existing telomere.  Centromeres are depicted as green ovals, telomeres by black 84 
and white rectangles and genes in colored squares.  (B) inter-chromosomal telomere 85 
fusion between short dysfunction telomeres (depicted), or with non-telomeric DSBs, can 86 
lead to the formation of dicentric chromosomes and the initiation of BFB cycles that can 87 
lead to the formation of non-reciprocal translations (NRT) and deletions.  This process 88 
can be prevented by chromosomal healing via the acquisition of new telomere. 89 
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